<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ulster Med J</journal-id><journal-id journal-id-type="pmc">ulstermedj</journal-id><journal-title>The Ulster Medical Journal</journal-title><issn pub-type="ppub">0041-6193</issn><publisher><publisher-name>Ulster Medical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8979783</article-id><article-id pub-id-type="pmc">2448590</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Clinical trial comparing artificial rupture of membranes plus oral PGE2 tablets versus artificial rupture of membranes plus intravenous oxytocin for induction of labour in primigravid patients at term.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nassief</surname><given-names>S. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McFaul</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rane</surname><given-names>A.</given-names></name></contrib></contrib-group><aff>West Dorset Hospital, Dorchester.</aff><pub-date pub-type="ppub"><month>11</month><year>1996</year></pub-date><volume>65</volume><issue>2</issue><fpage>145</fpage><lpage>148</lpage><abstract><p>We report the results of a pilot study conducted to compare the efficacy of oral prostaglandin E2 versus intravenous oxytocin in inducing labour after lower amniotomy in 20 primigravid patients at term. The results suggest no significant differences in the performance of each group for the induction to delivery interval, the mode of delivery, the Apgar score at five minutes or for third stage abnormalities. However, the use of oral PGE2 allows the patient unrestricted mobility and avoids the discomfort of i.v. infusions.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="ulstermedj00066-0049.tif" xlink:title="scanned-page" xlink:role="145" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="ulstermedj00066-0050.tif" xlink:title="scanned-page" xlink:role="146" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="ulstermedj00066-0051.tif" xlink:title="scanned-page" xlink:role="147" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="ulstermedj00066-0052.tif" xlink:title="scanned-page" xlink:role="148" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

